1. Home
  2. CINGW vs CRNX Comparison

CINGW vs CRNX Comparison

Compare CINGW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CRNX
  • Stock Information
  • Founded
  • CINGW N/A
  • CRNX 2008
  • Country
  • CINGW United States
  • CRNX United States
  • Employees
  • CINGW 13
  • CRNX N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CRNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CINGW Health Care
  • CRNX Health Care
  • Exchange
  • CINGW Nasdaq
  • CRNX Nasdaq
  • Market Cap
  • CINGW N/A
  • CRNX N/A
  • IPO Year
  • CINGW 2021
  • CRNX 2018
  • Fundamental
  • Price
  • CINGW $0.03
  • CRNX $33.39
  • Analyst Decision
  • CINGW
  • CRNX Strong Buy
  • Analyst Count
  • CINGW 0
  • CRNX 12
  • Target Price
  • CINGW N/A
  • CRNX $73.36
  • AVG Volume (30 Days)
  • CINGW N/A
  • CRNX 1.2M
  • Earning Date
  • CINGW N/A
  • CRNX 05-08-2025
  • Dividend Yield
  • CINGW N/A
  • CRNX N/A
  • EPS Growth
  • CINGW N/A
  • CRNX N/A
  • EPS
  • CINGW N/A
  • CRNX N/A
  • Revenue
  • CINGW N/A
  • CRNX $1,039,000.00
  • Revenue This Year
  • CINGW N/A
  • CRNX $356.40
  • Revenue Next Year
  • CINGW N/A
  • CRNX $700.38
  • P/E Ratio
  • CINGW N/A
  • CRNX N/A
  • Revenue Growth
  • CINGW N/A
  • CRNX N/A
  • 52 Week Low
  • CINGW N/A
  • CRNX $24.10
  • 52 Week High
  • CINGW N/A
  • CRNX $62.53
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CRNX 58.09
  • Support Level
  • CINGW N/A
  • CRNX $28.75
  • Resistance Level
  • CINGW N/A
  • CRNX $31.43
  • Average True Range (ATR)
  • CINGW 0.00
  • CRNX 1.81
  • MACD
  • CINGW 0.00
  • CRNX 0.71
  • Stochastic Oscillator
  • CINGW 0.00
  • CRNX 99.25

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: